date,title,source
Oct-26-18,Intellipharmaceutics Regains Compliance with Nasdaq Minimum Shareholders' Equity Listing Requirements,ACCESSWIRE
Nov-05-18,Intellipharmaceutics Announces Resignation of Chief Financial Officer,ACCESSWIRE
Nov-20-18,Intellipharmaceutics Reports Exclusive Distribution Agreements in Malaysia and Vietnam,ACCESSWIRE
Nov-21-18,Intellipharmaceutics Reports Exclusive Supply Agreement for its Abuse-Deterrent Oxycodone ER Product Candidate and Four Generic Drug Products in the Philippines,ACCESSWIRE
Nov-26-18,Intellipharmaceutics Announces Receipt of Nasdaq Notice,ACCESSWIRE
Nov-28-18,"The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings",Benzinga
Nov-28-18,Todays Research Reports on Stocks to Watch: IntelliPharmaCeutics International and Bristol-Myers Squibb,ACCESSWIRE
Jan-07-19,Intellipharmaceutics Announces Research and Development Program for a Pipeline of Pharmaceutical Cannabidiol Based Products,ACCESSWIRE
Jan-28-19,Intellipharmaceutics Receives Extension from Nasdaq Hearings Panel,ACCESSWIRE
Feb-20-19,Intellipharmaceutics Announces FDA Tentative Approval of Generic Pristiq(R),ACCESSWIRE
Feb-22-19,Intellipharmaceutics Announces Fiscal Year 2018 Results,ACCESSWIRE
Mar-19-19,Intellipharmaceutics Receives Nasdaq Listing Determination; To Begin Trading on the OTC Markets System,ACCESSWIRE
Mar-29-19,"U.S. FDA Acknowledges Receipt of Intellipharmaceutics' Resubmission of Oxycodone ER New Drug Application, Deems it a Complete Response, and Designates August 28, 2019 as Goal Date for Review",ACCESSWIRE
